Table 2.

Pharmacokinetic parameters of ethinylestradiol and levonorgestrel in plasma after single-dose administration of levonorgestrel-ethinylestradiol alone (treatment A) or with riociguat coadministration (treatment B) in the pharmacokinetic analysis set

	Ethinylestradiol		Levonorgestrel
Parameter	Levonorgestrel-ethinylestradiol alone	Levonorgestrel-ethinylestradiol plus riociguat	Levonorgestrel-ethinylestradiol alone	Levonorgestrel-ethinylestradiol plus riociguat
AUC, μg×h/L
Geometric mean	0.858	0.874	46.5	46.6
%CV (range)	30.1 (0.52–1.95)	28.5 (0.57–1.63)	40.1 (21.6–95.8)	33.3 (26.6–106)
Cmax, μg/L
Geometric mean	0.0572	0.0688	3.26	3.41
%CV (range)	28.6 (0.04–0.102)	30.6 (0.04–0.12)	34.4 (1.8–5.3)	29.7 (1.67–6.34)
tmax, hours, median (range)	1.50 (1.00–3.00)	1.00 (1.00–3.00)	1.00 (1.00–1.50)	1.00 (0.50–1.50)
t1/2, hours
Geometric mean	22.1	20.51	39.4	39.0
%CV (range)	22.1 (14.2–35.3)	24.7 (12.2–34.2)	23.5 (26.8–57.2)	22.8 (26.5–63.3)

^NoteAUC: area under plasma concentration–time curve; C_max: maximum concentration; CV: coefficient of variation; t_max: time to C_max; t_1/2: terminal elimination half-life.